Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | EYA3 | Q99504 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylic Acid SCHEMBL27451306 | 0.83 | KDM4E (0.35) | ALDH1A1HSD17B10TDP1MAPTCYP2C19 | |
| SCHEMBL13183865 | 0.83 | KDM4E (0.41) | ALDH1A1HSD17B10CYP1A2MAPTCYP2C19 | |
| SCHEMBL16684493 | 0.80 | MAPT (0.43) | TDP1MAPTEYA3GAA | |
| SCHEMBL27644444 | 0.79 | MAPT (0.49) | TSHRMAPT | |
| SCHEMBL9739681 | 0.78 | HTR2A (0.43) | CYP2A6ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL9935525 | 0.78 | TDP1 (0.35) | CYP2A6ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL1746782 | 0.78 | MAOB (0.40) | CYP2A6ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL28268580 | 0.78 | ALDH1A1 (0.35) | CYP2A6ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL6002448 | 0.78 | ALDH1A1 (0.35) | CYP2A6ALDH1A1TSHRHSD17B10TDP1 | |
| SCHEMBL21718711 | 0.78 | CCR4 (0.34) | CYP2A6ALDH1A1TSHRHSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3164465-B1 | IMPROVED PROCESSES FOR RECOVERING VALUABLE COMPONENTS FROM A CATALYTIC FAST PYROLYSIS PROCESS | ANELLOTECH INC (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-119523070-A | Walnut shell fumigating liquid and preparation method and application thereof | 新疆农业大学 | 2025-02-28 | — | — | CN | disclosed |
| CN-106574190-B | Improved process for recovering valuable components from catalytic fast pyrolysis process | 阿内洛技术股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-10954452-B2 | Processes for recovering valuable components from a catalytic fast pyrolysis process | ANELLOTECH, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190338195-A1 | PROCESSES FOR RECOVERING VALUABLE COMPONENTS FROM A CATALYTIC FAST PYROLYSIS PROCESS | ANELLOTECH, INC. | 2019-11-07 | — | — | US | disclosed |
| US-10351783-B2 | Processes for recovering valuable components from a catalytic fast pyrolysis process | ANELLOTECH, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180094197-A1 | PROCESSES FOR RECOVERING VALUABLE COMPONENTS FROM A CATALYTIC FAST PYROLYSIS PROCESS | ANELLOTECH, INC. | 2018-04-05 | — | — | US | disclosed |
| US-9790179-B2 | Processes for recovering valuable components from a catalytic fast pyrolysis process | ANELLOTECH, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9745291-B2 | PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof | Epizyme, Inc. (US) | 2017-08-29 | — | — | US | disclosed |
| EP-3164465-A2 | IMPROVED PROCESSES FOR RECOVERING VALUABLE COMPONENTS FROM A CATALYTIC FAST PYROLYSIS PROCESS | Anellotech, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| US-8940726-B2 | PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| CN-100497345-C | 2, 3-dihydro-6-nitroimidazolo [2,1-b] oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2009-06-10 | — | — | CN | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| CN-1878777-A | 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis | OTSUKA PHARMA CO LTD (JP) | 2006-12-13 | — | — | CN | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | CYP2A6 1153/4885ALDH1A1 412/4885TSHR 162/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | CYP2A6 2460/4885ALDH1A1 4596/4885TSHR 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.